Clinical trials: Schizophrenia Spectrum Disorders
Schizophrenia, Bipolar Disorder
Person-Centered Versus Measurement-Based Care in Mental Health
Fifteen minutes is the typical length of an outpatient medication management appointment for people with serious mental health conditions.
- Conditions
- Schizophrenia, Bipolar Disorder, Major Depression
- Trial name
- PCORI-SDM (NCT02507349)
- Testing
- Person-Centered Care, Measurement-Based Care
- Where
- 2 sites in United States
- Volunteers
- 2,443 people
- Sponsor
- University of Pittsburgh
Schizophrenia, Medication Nonadherence
Reducing the Burden of Chronic Psychotic Disorders in Tanzania (CAPACITY)
The proposed, three phase project will refine and test a first-ever care approach in SSA that combines LAI with a behavioral program specifically intended to promote medication adherence in chronic psychotic disorders (CPDs).
- Conditions
- Schizophrenia, Medication Nonadherence, Schizo Affective Disorder
- Trial name
- CAPACITY (NCT04327843)
- Testing
- Customized Adherence Enhancement, Haloperidol Decanoate
- Where
- Tanzania
- Volunteers
- 22 people
- Sponsor
- Case Western Reserve University
Metabolic Syndrome, Schizophrenia
A Phase 4 Study to Assess the Effects of Aripiprazole Versus Other Atypical Antipsychotics in the Treatment of Schizophrenic Patients With Metabolic Syndrome
258 patients who have been treated for at least 3 months with oral olanzapine, risperidone or quetiapine in the treatment of schizophrenia and currently presenting with metabolic syndrome, will be randomized to: i) aripiprazole…
- Trial name
- NCT00508157
- Testing
- Aripiprazole, Continued Antipsychotic (Risperidone or Quetiapine or Olanzapine)
- Where
- 30 sites in Belgium, Czechia and 7 more
- Volunteers
- 125 people
- Sponsor
- Bristol-Myers Squibb
Schizophrenia
A Study of ALKS 3831 in Adults With Schizophrenia
This is a Phase 2, randomized, placebo-controlled multicenter study, which will be conducted in 2 parts. The study duration for each subject will be approximately 33 weeks and will include 25 study visits.
- Trial name
- NCT01903837
- Testing
- Samidorphan (Low Dose), Samidorphan (Medium Dose), Samidorphan (High Dose)
- Where
- 61 sites in United States, Bulgaria and 1 more
- Volunteers
- 347 people
- Sponsor
- Alkermes, Inc.
Bipolar Disorder, Schizoaffective Disorder
Probiotics to Prevent Relapse After Hospitalization for Mania
The purpose of this study is to determine if taking a probiotic supplement versus a placebo will lower rates of relapse and improve the clinical course among participants who have been hospitalized for mania.
- Trial name
- NCT01731171
- Testing
- Probiotic Supplement, Inert Compound
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- Sheppard Pratt Health System
Schizophrenia
An Open Trial of Allopurinol in Patients With Poorly Responsive Schizophrenia
This is a four week open label trial of ALLOPURINOL to the treatment regime of ten (10) poorly responsive patients with schizophrenia, monitoring their response and side-effects. No change in medication is required.
- Trial name
- NCT00823199
- Testing
- Allopurinal
- Volunteers
- 10 people
- Sponsor
- Bronx Psychiatric Center
Schizophrenia, Schizoaffective Disorder
Preventing Relapse in Schizophrenia: Oral Antipsychotics Compared To Injectables: Evaluating Efficacy
This study is designed to find out whether taking antipsychotic medication once every two weeks by injection compared to taking daily oral medication will help people with schizophrenia maintain better control of their symptoms.
- Trial name
- PROACTIVE (NCT00330863)
- Testing
- Risperidone microspheres, Risperidone, Olanzapine
- Where
- 8 sites in United States
- Volunteers
- 357 people
- Sponsor
- Northwell Health
Insomnia, Schizophrenia
Randomized, Controlled, Double Blind Trial of Eszopiclone for Insomnia Associated With Schizophrenia
The major goal of this project is to investigate established insomnia treatments in a schizophrenia population to see if the improved sleep leads to overall better quality of life.
- Conditions
- Insomnia, Schizophrenia, Schizoaffective Disorder, Sleep Disorders
- Trial name
- NCT00645944
- Testing
- Eszopiclone
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Yale University
Schizophrenia
Safety, Tolerability, Pharmacokinetics and Efficacy of 180 mg Subcutaneous Risperidone From 6 mg Oral Risperidone
This study evaluates PERSERIS at a higher dose than what has been administered in previous clinical trials. Subjects with stable schizophrenia on a dose of 5-6 mg oral risperidone will be switched to PERSERIS at the higher dose…
- Trial name
- NCT03978832
- Testing
- PERSERIS, Risperidone
- Where
- United States
- Volunteers
- 69 people
- Sponsor
- Indivior Inc.
Schizophrenia
Long Term Study of RBP 7000 in the Treatment of Subjects With Schizophrenia
This is a Phase 3, open label study administering RBP-7000 in the treatment of patients with schizophrenia. Study will assess the long-term safety and tolerability of RBP-7000 subcutaneous (SC) injections in subjects with…
- Trial name
- NCT02203838
- Testing
- RBP-7000
- Where
- 48 sites in United States
- Volunteers
- 500 people
- Sponsor
- Indivior Inc.
SCHIZOPHRENIA 1 (Disorder), Nicotine Use
Behavioral Impact and Neural Correlates of Network-based Brain Stimulation in Schizophrenia
The primary aims of this study are to investigate the behavioral effects of applying targeted transcranial magnetic stimulation (TMS) to a node of the brain network subserving attention in schizophrenia and schizoaffective…
- Trial name
- NCT07190352
- Testing
- iTBS to the DMN, cTBS to the DMN
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Beth Israel Deaconess Medical Center
Major Depression, Bipolar Depression
The Use of Galantamine HBr (Reminyl) in Electroconvulsive Therapy: Impact on Mood and Cognitive Functioning
The purpose of the study is to see if galantamine HBr (Razadyne) is safe and can help treat problems with thinking and memory caused by electroconvulsive therapy (ECT).
- Conditions
- Major Depression, Bipolar Depression, Schizoaffective Disorder
- Trial name
- Galantamine (NCT00566735)
- Testing
- Razadyne
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Massachusetts General Hospital
Schizophrenia, Schizoaffective Disorder
Tocilizumab as Add-On Treatment For Residual Positive, Negative, and Cognitive Symptoms of Schizophrenia
Randomized, double-blind clinical trial of tocilizumab vs. placebo as add-on treatment for residual positive, negative, and cognitive symptoms in schizophrenia.
- Trial name
- NCT02034474
- Testing
- Tocilizumab
- Where
- United States
- Volunteers
- 59 people
- Sponsor
- New York State Psychiatric Institute
Depressive Disorder, Bipolar Disorder
Nonconvulsive Electrotherapy: a Proof-of-concept Trial
This study involves pilot testing of a modified version of a proven treatment for mental illness. The treatment, electroconvulsive therapy (ECT) is used to treat more than 100,000 Americans yearly.
- Conditions
- Depressive Disorder, Bipolar Disorder, Schizoaffective Disorder
- Trial name
- NCT01065597
- Testing
- Nonconvulsive electrotherapy
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- University of Maryland, College Park
Schizophrenia, Schizoaffective Disorder
A Study to Assess the Effects of RO6889450 (Ralmitaront) in Participants With Schizophrenia or Schizoaffective Disorder and Negative Symptoms
This study investigates the effects of RO6889450 on the negative symptoms associated with schizophrenia and schizoaffective disorder.
- Trial name
- NCT03669640
- Testing
- RO6889450
- Where
- 45 sites in United States, Japan and 2 more
- Volunteers
- 131 people
- Sponsor
- Hoffmann-La Roche
Schizophrenia
A Clinical Trial of Lurasidone in Treatment of Schizophrenia
This is a randomized, double-blind, double-dummy, parallel- controlled, adjustable dose, non-inferiority and multicentre study designed to evaluate the efficacy and safety of lurasidone on schizophrenia for 6 weeks treatment, and…
- Trial name
- NCT02002832
- Testing
- Lurasidone tablets, Risperidone tablets
- Where
- 15 sites in China
- Volunteers
- 388 people
- Sponsor
- Marubeni Pharmaceuticals (Suzhou) Co., Ltd.
Schizophrenia
Efficacy and Safety of Adjunctive Pimavanserin for the Treatment of Schizophrenia (ENHANCE-1)
To evaluate the efficacy and safety of adjunctive pimavanserin compared with adjunctive placebo in the treatment of schizophrenia
- Trial name
- NCT02970292
- Testing
- Pimavanserin
- Where
- 105 sites in United States, Bulgaria and 8 more
- Volunteers
- 396 people
- Sponsor
- ACADIA Pharmaceuticals Inc.
Schizophrenia, Schizoaffective Disorder
Naltrexone for Antipsychotic-Induced Weight Gain
This study is designed to look at the effects of naltrexone on weight loss in individuals treated with antipsychotic medications.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Bipolar Disorder
- Trial name
- NTX (NCT01866098)
- Testing
- Naltrexone
- Where
- United States
- Volunteers
- 144 people
- Sponsor
- Yale University
Schizophrenia, Schizophreniform Disorder
Biomarkers in First Episode Schizophrenia
This study will identify and evaluate relevant biomarkers and structural brain imaging for understanding potential biological illness related mechanisms in medication-naïve subjects with early psychosis before and after…
- Conditions
- Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, Depressed Type
- Trial name
- NCT02033382
- Where
- United States
- Volunteers
- 165 people, healthy volunteers welcome
- Sponsor
- NYU Langone Health
Agitation
Treating Acutely Agitated Patients With Asenapine Sublingual Tablets
Our proposal is to administer asenapine to patients who are clinically agitated and in need of immediate intervention. At present there are no controlled studies that we know of that explores the use of asenapine for this…
- Trial name
- NCT01400113
- Testing
- Asenapine
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Unity Health Toronto